Total Payments
$1.1M
2024 Payments
$182,550
Companies
48
Transactions
1,906
Medicare Patients
2,522
Medicare Billing
$209,069
Payment Breakdown by Category
Other$751,215 (69.9%)
Travel$155,322 (14.4%)
Research$77,203 (7.2%)
Consulting$52,933 (4.9%)
Food & Beverage$37,872 (3.5%)
Education$304.34 (0.0%)
Gifts$240.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $743,167 | 347 | 69.1% |
| Travel and Lodging | $155,322 | 537 | 14.4% |
| Unspecified | $77,203 | 4 | 7.2% |
| Consulting Fee | $52,933 | 26 | 4.9% |
| Food and Beverage | $37,872 | 968 | 3.5% |
| Honoraria | $3,483 | 2 | 0.3% |
| Long term medical supply or device loan | $3,290 | 3 | 0.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,275 | 1 | 0.1% |
| Education | $304.34 | 17 | 0.0% |
| Gift | $240.00 | 1 | 0.0% |
Payments by Type
General
$997,886
1,902 transactions
Research
$77,203
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| JAZZ PHARMACEUTICALS INC. | $222,253 | 273 | $0 (2024) |
| Amarin Pharma Inc. | $207,677 | 334 | $0 (2023) |
| EISAI INC. | $139,297 | 239 | $0 (2022) |
| Amgen Inc. | $124,911 | 227 | $0 (2024) |
| Eli Lilly and Company | $77,203 | 4 | $0 (2024) |
| IDORSIA PHARMACEUTICALS US INC | $75,470 | 84 | $0 (2024) |
| Axsome Therapeutics, Inc. | $57,699 | 71 | $0 (2024) |
| HARMONY BIOSCIENCES LLC | $53,197 | 92 | $0 (2024) |
| Merck Sharp & Dohme LLC | $38,723 | 65 | $0 (2022) |
| SANOFI-AVENTIS U.S. LLC | $37,436 | 48 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $182,550 | 184 | Eli Lilly and Company ($76,583) |
| 2023 | $174,826 | 278 | JAZZ PHARMACEUTICALS INC. ($66,450) |
| 2022 | $116,255 | 181 | JAZZ PHARMACEUTICALS INC. ($74,818) |
| 2021 | $100,360 | 239 | Eisai Inc. ($41,212) |
| 2020 | $151,578 | 270 | Eisai Inc. ($96,415) |
| 2019 | $106,457 | 233 | Amarin Pharma Inc. ($70,188) |
| 2018 | $120,182 | 217 | Amarin Pharma Inc. ($54,373) |
| 2017 | $122,881 | 304 | Amarin Pharma Inc. ($69,025) |
All Payment Transactions
1,906 individual payment records from CMS Open Payments — Page 1 of 77
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Philips North America LLC | (8269) DreamStation Cpap (Device) | Long term medical supply or device loan | In-kind items and services | $1,098.83 | General |
| Category: Medical Device | ||||||
| 12/19/2024 | Axsome Therapeutics, Inc. | Sunosi (Drug) | Education | In-kind items and services | $2.82 | General |
| Category: Neurology | ||||||
| 12/17/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $32.17 | General |
| Category: NEUROLOGY | ||||||
| 12/13/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $16.30 | General |
| Category: Diabetes Care | ||||||
| 12/11/2024 | Axsome Therapeutics, Inc. | Sunosi (Drug) | Food and Beverage | In-kind items and services | $114.43 | General |
| Category: Neurology | ||||||
| 12/11/2024 | Axsome Therapeutics, Inc. | Sunosi (Drug) | Food and Beverage | In-kind items and services | $31.02 | General |
| Category: Neurology | ||||||
| 12/11/2024 | Axsome Therapeutics, Inc. | Sunosi (Drug) | Education | In-kind items and services | $2.82 | General |
| Category: Neurology | ||||||
| 12/11/2024 | Axsome Therapeutics, Inc. | Sunosi (Drug) | Education | In-kind items and services | $1.33 | General |
| Category: Neurology | ||||||
| 12/10/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $8.20 | General |
| Category: Endocrinology | ||||||
| 12/03/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $18.44 | General |
| Category: Obesity | ||||||
| 11/28/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,030.00 | General |
| Category: NEUROLOGY | ||||||
| 11/28/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Travel and Lodging | In-kind items and services | $80.40 | General |
| Category: NEUROLOGY | ||||||
| 11/28/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Travel and Lodging | In-kind items and services | $73.00 | General |
| Category: NEUROLOGY | ||||||
| 11/28/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Travel and Lodging | In-kind items and services | $26.00 | General |
| Category: NEUROLOGY | ||||||
| 11/28/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $23.35 | General |
| Category: NEUROLOGY | ||||||
| 11/28/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $13.53 | General |
| Category: NEUROLOGY | ||||||
| 11/21/2024 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $102.77 | General |
| Category: Insomnia | ||||||
| 11/16/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Travel and Lodging | In-kind items and services | $192.88 | General |
| Category: NEUROLOGY | ||||||
| 11/15/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $120.20 | General |
| Category: NEUROLOGY | ||||||
| 11/12/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $117.69 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/04/2024 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $953.75 | General |
| Category: Insomnia | ||||||
| 11/04/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $13.93 | General |
| Category: NEUROLOGY | ||||||
| 11/01/2024 | 3B Medical, Inc. | LUNA (Device) | Food and Beverage | Cash or cash equivalent | $26.56 | General |
| Category: VENTILATOR, NON-CONTINUOUS (RESPIRATOR) | ||||||
| 10/30/2024 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,087.50 | General |
| Category: Insomnia | ||||||
| 10/30/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $5.71 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | Eli Lilly and Company | $39,978 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | Eli Lilly and Company | $29,405 | 1 |
| A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | Eli Lilly and Company | $7,820 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 405 | 599 | $103,450 | $42,497 |
| 2022 | 7 | 529 | 663 | $106,473 | $41,733 |
| 2021 | 9 | 736 | 1,100 | $131,347 | $67,788 |
| 2020 | 10 | 852 | 1,116 | $124,039 | $57,051 |
Total Patients
2,522
Total Services
3,478
Medicare Billing
$209,069
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 158 | 303 | $54,925 | $24,691 | 45.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 143 | 191 | $25,500 | $10,275 | 40.3% |
| 95810 | Sleep study in sleep lab (6 years or older) | Facility | 2023 | 36 | 37 | $9,700 | $2,983 | 30.7% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Facility | 2023 | 28 | 28 | $6,800 | $2,392 | 35.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 26 | 26 | $4,775 | $1,694 | 35.5% |
| 95806 | Sleep study including heart rate, breathing, airflow, and effort | Office | 2023 | 14 | 14 | $1,750 | $461.58 | 26.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 185 | 282 | $50,550 | $20,408 | 40.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 196 | 229 | $31,425 | $13,273 | 42.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 23 | 23 | $6,450 | $2,394 | 37.1% |
| 95810 | Sleep study in sleep lab (6 years or older) | Facility | 2022 | 25 | 25 | $7,500 | $2,243 | 29.9% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Facility | 2022 | 17 | 17 | $5,950 | $1,618 | 27.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 23 | 23 | $4,150 | $1,607 | 38.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 60 | 64 | $448.00 | $189.35 | 42.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 230 | 463 | $69,450 | $39,315 | 56.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 144 | 169 | $17,745 | $10,611 | 59.8% |
| 95811 | Sleep monitoring of patient (6 years or older) in sleep lab with continued pressured respiratory assistance by mask or breathing tube | Office | 2021 | 46 | 47 | $13,959 | $4,433 | 31.8% |
| 95810 | Sleep monitoring of patient (6 years or older) in sleep lab | Office | 2021 | 42 | 43 | $12,255 | $3,936 | 32.1% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 44 | 44 | $6,600 | $3,430 | 52.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 25 | 25 | $5,625 | $3,097 | 55.1% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 38 | 38 | $2,850 | $1,399 | 49.1% |
| 99211 | Established patient outpatient visit, minimal presenting problem | Office | 2021 | 41 | 42 | $1,260 | $880.68 | 69.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 126 | 229 | $1,603 | $684.35 | 42.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 202 | 303 | $45,450 | $22,973 | 50.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 223 | 257 | $26,985 | $11,581 | 42.9% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 126 | 158 | $16,590 | $8,695 | 52.4% |
About Dr. Michael Ledet, MD
Dr. Michael Ledet, MD is a Sleep Medicine healthcare provider based in Daphne, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/13/2005. The National Provider Identifier (NPI) number assigned to this provider is 1407854482.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Ledet, MD has received a total of $1.1M in payments from pharmaceutical and medical device companies, with $182,550 received in 2024. These payments were reported across 1,906 transactions from 48 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($743,167).
As a Medicare-enrolled provider, Ledet has provided services to 2,522 Medicare beneficiaries, totaling 3,478 services with total Medicare billing of $209,069. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Sleep Medicine
- Location Daphne, AL
- Active Since 07/13/2005
- Last Updated 04/05/2022
- Taxonomy Code 207QS1201X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1407854482
Products in Payments
- Vascepa (Drug) $207,677
- XYWAV (Drug) $186,149
- Dayvigo (Drug) $139,297
- Repatha (Biological) $124,750
- QUVIVIQ (Drug) $75,470
- Sunosi (Drug) $57,699
- Wakix (Drug) $46,704
- BELSOMRA (Drug) $38,394
- PRALUENT (Drug) $37,367
- SUNOSI (Drug) $34,909
- NEXLIZET (Drug) $16,309
- WAKIX (Drug) $6,493
- PRALUENT ALIROCUMAB INJECTION (Biological) $5,123
- PRALUENT (Biological) $4,920
- (8269) DreamStation Cpap (Device) $3,290
- EVKEEZA (Biological) $3,039
- LEQVIO (Drug) $922.63
- Ozempic (Drug) $698.73
- NEXLETOL (Drug) $561.45
- JARDIANCE (Drug) $402.02
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.